Approval / Commercialization
Resources and insights tagged approval commercialization from Pedestal Health.
Publications
47
Total Publications
12
Abstract/Manuscript
6
Oral Presentation
29
Poster Presentation
2026 · Poster Presentation · Amgen · Dermatology
Real world characteristics and burden of patients initiating advanced systemic therapy in the TARGET-DERM atopic dermatitis registry
Read more →2026 · Poster Presentation · AbbVie · Gastroenterology
Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO
Read more →2026 · Poster Presentation · AbbVie · Gastroenterology
Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO
Read more →2025 · Poster Presentation · Genentech · Hepatology
Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry
Read more →2025 · Poster Presentation · Merck · Hepatology
Real-World Treatment Patterns Among US Adults with Unresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT)
Read more →2025 · Poster Presentation · Methods/Pharmacoepi
Power Vs. Precision When Estimating Risk Differences Using Observational Data? A Case Study From TARGET-IBD
Read more →2025 · Poster Presentation · Madrigal · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions
Read more →2025 · Poster Presentation · Methods/Pharmacoepi
Missing the Mark: Treat-to-Target Gaps in Real-World Ulcerative Colitis Care
Read more →2025 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Leveraging public health infrastructures to support sexual health for women living in the Southern United States
Read more →2025 · Poster Presentation · Methods/Pharmacoepi
Treat-to-Target Gaps in Crohn’s Disease: Insights from Real-World Practice
Read more →2024 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting
Read more →2024 · Poster Presentation · Merck · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort
Read more →2024 · Poster Presentation · Merck · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort
Read more →2024 · Poster Presentation · UNC · Hepatology
Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH
Read more →2024 · Poster Presentation · University of Miami (FL) · Hepatology
Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep Versus Adequate ALP Response to UDCA
Read more →2024 · Poster Presentation · Novartis AG · Dermatology
Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
Read more →2024 · Abstract/Manuscript · Heinrich Heine University Dusseldorf/German Diabetes Center
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort
Read more →2024 · Oral Presentation · Saint Louis University · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality
Read more →2024 · Abstract/Manuscript · Northwestern University
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry
Read more →2024 · Oral Presentation · Novartis AG · Dermatology
Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Predicting Loss of Remission in Crohn's Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD
Read more →2024 · Poster Presentation · AbbVie Inc. · Dermatology
Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry (Fall Clinical 2024)
Read more →2023 · Poster Presentation · AbbVie Inc. · Dermatology
Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from TARGET-DERM registry (RAD Winter 2023)
Read more →2023 · Poster Presentation · Dermatology
The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: Real-world Insights from TARGET-DERM AD
Read more →2023 · Abstract/Manuscript · National University Hospital
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Read more →2023 · Oral Presentation · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non–Muscle-Invasive Bladder Cancer
Read more →2022 · Poster Presentation · University of Chicago · Gastroenterology
The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD
Read more →2022 · Poster Presentation · Bristol Myers Squibb · Gastroenterology
Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD
Read more →2022 · Abstract/Manuscript · Mayo Clinic
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
Read more →2022 · Abstract/Manuscript · Northwestern University
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
Read more →2022 · Oral Presentation · Hepatology
The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC (APASL)
Read more →2021 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort
Read more →2021 · Poster Presentation · AbbVie Inc. · Gastroenterology
Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis
Read more →2021 · Abstract/Manuscript · University of Michigan
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study
Read more →2020 · Poster Presentation · Heinrich-Heine University Düsseldorf · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice
Read more →2020 · Poster Presentation · Hepatology
The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC
Read more →2020 · Abstract/Manuscript · Amgen Inc.
Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States
Read more →2020 · Oral Presentation · Hepatology
Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH
Read more →2019 · Poster Presentation · University of Miami (FL) · Hepatology
Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort (DDW 2019)
Read more →2018 · Poster Presentation · University of Michigan · Hepatology
Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)
Read more →2018 · Poster Presentation · Stanford · Hepatology
Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)
Read more →2018 · Oral Presentation · Amgen Inc. · Methods/Pharmacoepi
Real-world patterns of romiplostim treatment in adults with primary immune thrombocytopenia in the United States
Read more →2017 · Poster Presentation · University of Michigan · Hepatology